Specialty medications, which can cost between $10,000 and upward of $5 million, now account for 52% of U.S. pharmaceutical sales, according to a Dec. 30 report from the Healthcare Distribution ...

Q4 2025 Management View CEO Stephan Tanda emphasized "very strong top line performance" for Q4, with reported sales growing 14% to $963 million and core sales up 5%. Tanda noted, "Adjusted EBITDA ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. Nevertheless, at least as far as ...

LONDON--(BUSINESS WIRE)--As coronavirus continues to wreak havoc across industries, Quantzig’s sales analytics experts analyze the recent challenges in the pharmaceutical industry and explain why a ...

The company reaffirmed its guidance for 2025, projecting Jornay PM net revenue to exceed $135 million, reflecting at least 34% annual growth. Management expects the expanded sales force to ...

Nearly 96 percent of U.S. pharmaceutical sales were brought to the market through pharmaceutical distributors in 2016, according to a new report published by the HDA Research Foundation, a healthcare ...

Total GAAP revenue reached $15.7 million in Q2 2025, outpacing the $13.8 million GAAP analyst estimate. Selling, general and administrative expenses (GAAP) rose to $54.3 million, driving a net loss ...

Please provide your email address to receive an email when new articles are posted on . Boy, I know that there are some really terrible jobs in the extended health care universe, but it sure seems ...

CEO David Zaccardelli highlighted the continued success of the Ohtuvayre launch for COPD maintenance treatment, with net product sales of $71.3 million in Q1 2025, nearly doubling from the previous ...

The latest announcement is out from Solasia Pharma KK ( (JP:4597)). Solasia Pharma K.K. has announced a change in its sales partner for the oral liquid product, episil, in China. The company is ...